SEC Tracker
Get the app

Collegium Pharmaceutical COLL

Collegium Pharmaceutical reported $216.34 million in revenue for Q3 2026

Form
10-Q
Filed
Importance
Notable
  1. Revenue: $216.34 million for the three months ended Sep 30, 2026
  2. Net income: $21.76 million for the three months ended Sep 30, 2026
  3. Diluted EPS: $0.60 for the three months ended Sep 30, 2026
  4. Cash and equivalents: $144.8 million at Sep 30, 2026

Written from the 10-Q on EDGAR. AI can make mistakes. Check the filing.

Open in the appGet the appView on EDGAR

Get an email when Collegium Pharmaceutical files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Same SIC code (2834) and public float $300M to $2B, nearest public float first, as each company reports it on its annual report cover.

  1. CorMedix CRMD public float $910M, Jun 30, 2025
  2. Geron GERN public float $861M, Jun 30, 2025
  3. Harrow HROW public float $1.0B, Jun 30, 2025
  4. Syndax Pharmaceuticals SNDX public float $799M, Jun 30, 2025
  5. Phibro Animal Health PAHC public float $764M, Dec 31, 2025

Data on this page was fetched . The filing on SEC.gov is the record.